Berzosertib

DB11794InvestigationalSmall molecule

Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase ATR
Curator reviewed
Formula / weight: C₂₄H₂₅N₅O₃S · 463.56 g/mol (avg)
Code names: M 6620 · VE-822 · VX-970

Resolves to

Compound

UNIIL423PRV3V3CAS1232416-25-9ChEMBLCHEMBL3989870ChEBI131166PubChem59472121

Structure

InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-NSMILESCNCC1=CC=C(C=C1)C1=NOC(=C1)C1=NC(=CN=C1N)C1=CC=C(C=C1)S(=O)(=O)C(C)C

Targets

Q13535ATR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

24Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Berzosertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account